Trial Profile
A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 04 Oct 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
- 24 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.